Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

270.24

+2.87 (1.07%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Aug 21, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has shown some volatility recently, primarily due to performance issues in its cardio business, despite reporting a solid beat-and-raise quarter. The company has successfully addressed past legal challenges related to talcum powder, minimizing the overhang of these lawsuits. Analysts are optimistic about JNJ’s upcoming earnings report expected on July 15, anticipating positive news about its oncology drugs and orthopedic business, although caution persists due to erratic stock movements following disclosure of results. The spin-off of the orthopedics division is viewed positively as it shifts focus towards higher-margin pharmaceutical and medical device sectors. Overall, JNJ is seen as a solid investment due to its strong drug pipeline and improved balance sheet, even as the company navigates its litigation concerns.

Consensus

Buy

Valuation

Fair Value

Similar

PAST TOP PICK

(A Top Pick Aug 12/11. Up 1.67%.)

BUY

Good holding, defensive, blend in with growth stocks in a portfolio. Has been held back a little because of issues such as recalls on the consumer side.

PAST TOP PICK

(A Top Pick Sept 29/10. Up 6.77%.) Reasonable valuation and a decent dividend. A core defensive holding.

PAST TOP PICK

(Top pick Aug 10/10, Up 8.12%) Health care should be at the top of the list now.

BUY

Some operation issues that he believes are resolved right now. Good pipeline of drugs. Issued 10-year debt at 3% but divined is higher. He would want to move from bonds to equity.

TOP PICK

Capable of withstanding a number of different issues, which it has. 8.5% earnings yield and 3.6% dividend yield.

PAST TOP PICK

(A Top Pick Aug 10/10. Up 8.52%.) Dividend is now approaching 4%. Still a Buy.

BUY

Historically, healthcare stocks do very well from around June through to September. Has been testing and breaking through new highs in the last couple of days.

Wealthica Track your Stocks in your Watch List

TOP PICK

The McDonald‘s in healthcare. Yield of 3.6%. Cash flow yield of 7.3%. Top line growth is still pretty good. Strong pipeline.

COMMENT

Should hold quite nicely during the bald period of spring and summer. If looking for extreme long-term growth, he is not sure you'll find it in this one. Expected to grow in the mid-single digit growth rate annually.

BUY

Cheap. Model $72.81, 9% upside. Good long-term hold. He finds more value elsewhere.

HOLD

Grown dividend 40 years in a row and earnings significantly over time. With aging population they will do very, very well. Prefers his Top Pick.

BUY

Worldwide franchise. Acquiring a Scandinavian company and he looks forward to a great long term reward. 3.5% yield.

DON'T BUY

Fits the bill for him for 2 reasons. 1) A consumer non-durable and 2) it’s a healthcare company. Healthcare has been an under performer and is pretty cheap here. One of this company’s problems is in their consumer products McNeil division, which has had some massive recalls. Pennsylvania manufacturing plant has been closed.

BUY

Really likes this one. Even more compelling now as a Canadian because of the currency exchange. A consistent cash flow generator. Has the pharma arm, which is always in distress but their consumer products side is so strong. 40%-50% of revenue comes from overseas. Great way to expose yourself to the 3rd world without taking on the risks. Operating metrics have increased. Really cheap.

Showing 421 to 435 of 628 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Johnson & Johnson (JNJ)